Thrombosis and systemic lupus erythematosus: The hopkins lupus cohort perspective

Research output: Contribution to journalShort surveypeer-review

Abstract

Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.

Original languageEnglish (US)
Pages (from-to)191-193
Number of pages3
JournalScandinavian Journal of Rheumatology
Volume25
Issue number4
DOIs
StatePublished - Jan 1 1996

Keywords

  • Anticardiolipin
  • Antiphospholipid antibodies
  • Lupus anticoagulant
  • Thrombosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'Thrombosis and systemic lupus erythematosus: The hopkins lupus cohort perspective'. Together they form a unique fingerprint.

Cite this